Protein production in transgenic potato plants having suppressed expression of patatin and CD4B

Patent metadata

Field	Value
Publication number	US-9803211-B2
Application number	US-201414897164-A
Country	US
Kind code	B2
Filing date	Jun 13, 2014
Priority date	Jun 14, 2013
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

The present disclosure relates to methods and constructs for producing heterologous peptides and proteins in plants in a safe and controlled manner. One aspect of the present invention provides a method of producing heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest and a marker gene, a nucleotide sequence capable of suppressing patatin expression, along with a nucleotide sequence capable of suppressing CD4B expression, and/or a nucleotide sequence capable of overexpressing P19. Another aspect of the invention provides a method of producing a heterologous protein in a transformed potato plant using an expression cassette comprising a gene coding for a protein or peptide of interest, a marker gene, a transit peptide sequence, and a nucleotide sequence capable of suppressing ADP glucose pyrophosphorylase expression.

First claim

What is claimed is:

1. A method of producing a heterologous protein or peptide of interest, the method comprising the steps of:
a. transforming a potato plant with an expression cassette, the expression cassette comprising (i) a nucleotide sequence capable of suppressing patatin expression; (ii) a nucleotide sequence capable of suppressing CD4B expression wherein the nucleotide sequence capable of suppressing CD4B comprises SEQ ID NO: 5 and SEQ ID NO: 6; (iii) a marker gene; and (iv) a gene coding for a heterologous protein or peptide of interest;
b. cultivating the transformed potato plant; and
c. extracting the heterologous protein or peptide of interest from the transformed potato plant.

2. The method of claim 1 , wherein the nucleotide sequence capable of suppressing patatin expression comprises antisense and sense sequences of patatin as set forth in SEQ ID NO: 3 and SEQ ID: 4.

3. The method of claim 1 , wherein the marker gene is selected from a group consisting of GFP, EGFP, GUS, LUX, CAH, SPT, NPTII, HPT, APHIV, BAR, PAT, CHS, AHAS, and flavonoid synthesis genes.

4. The method of claim 1 , wherein the protein of interest is selected from a group consisting of interleukin-2, hirudin, insulin, interferons, lactoferrin, hemoglobin, erythropoietin, epidermal growth factor, anthrax vaccines, cholera vaccine, DPT vaccine, hib vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, HPV vaccine, influenza vaccine, Japanese Encephalitis vaccine, MMR vaccine, MMRV vaccine, pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, polio vaccine, rotavirus vaccine, smallpox vaccine, tuberculosis vaccine, typhoid vaccine, yellow fever vaccine, parvovirus vaccine, distemper vaccine, adenovirus vaccine, parainfluenza vaccine, bordetella vaccine, rabies vaccine, leptospirosis vaccine, lyme vaccine, corona vaccine, round/hookworm vaccine, dewormer vaccine, RNFN vaccine, and HIV vaccine.

5. A method of producing a heterologous protein or peptide of interest, the method comprising the steps of:
a. transforming a potato plant with an expression cassette, the expression cassette comprising (i) a nucleotide sequence capable of suppressing patatin expression; (ii) a nucleotide sequence capable of suppressing CD4B expression wherein the nucleotide sequence capable of suppressing CD4B comprises SEQ ID NO: 5 and SEQ ID NO: 6; (iii) a nucleotide sequence capable of overexpressing P19; (iv) a marker gene; and (v) a gene coding for a heterologous protein or peptide of interest;
b. cultivating the transformed potato plant; and
c. extracting the heterologous protein or peptide of interest from the transformed potato plant.

6. The method of claim 5 , wherein the nucleotide sequence capable of suppressing patatin expression comprises antisense and sense sequences of patatin as set forth in SEQ ID NO: 3 and SEQ ID: 4; and wherein the nucleotide sequence capable of overexpressing P19 comprises the P19 sequence as set forth in SEQ ID NO: 2.

7. The method of claim 5 , wherein the marker gene is selected from a group consisting of GFP, EGFP, GUS, LUX, CAH, SPT, NPTII, HPT, APHIV, BAR, PAT, CHS, AHAS, and flavonoid synthesis genes.

8. The method of claim 5 , wherein the protein of interest is selected from a group consisting of interleukin-2, hirudin, insulin, interferons, lactoferrin, hemoglobin, erythropoietin, epidermal growth factor, anthrax vaccines, cholera vaccine, DPT vaccine, hib vaccine, hepatitis A vaccine, hepatitis B vaccine, hepatitis C vaccine, HPV vaccine, influenza vaccine, Japanese Encephalitis vaccine, MMR vaccine, MMRV vaccine, pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine, polio vaccine, rotavirus vaccine, smallpox vaccine, tuberculosis vaccine, typhoid vaccine, yellow fever vaccine, parvovirus vaccine, distemper vaccine, adenovirus vaccine, parainfluenza vaccine, bordetella vaccine, rabies vaccine, leptospirosis vaccine, lyme vaccine, corona vaccine, round/hookworm vaccine, dewormer vaccine, RNFN vaccine, and HIV vaccine.

Assignees

• Simplot Co J R

Inventors

• Peet Richard C
• Rommens Caius
• Chretien Robert
• Yan Hua
• Osumi Teruko

Classifications

• C12N15/8251 Primary

  Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis · CPC title

• A01H5/04

  Stems · CPC title

• C12N15/8218 Primary

  Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS] · CPC title

• C12N15/8257

  for the production of primary gene products, e.g. pharmaceutical products, interferon · CPC title